Bristol Myers Squibb Company
https://www.bms.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bristol Myers Squibb Company
Oncology Reinvents Itself To Retain Position As Biotech Investors’ Darling
Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.
Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology
After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO
Development Versus Dealmaking: How To Obtain A Blockbuster
Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.
EHA Preview: Agios Takes Spotlight In Thalassemia
The company expects to have data from transfusion-dependent and non-transfusion dependent patients this year, with a potential expanded US approval in 2025 for Pyrukynd.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Adnexus Therapeutics, Inc.
- Allied-Bristol Life Sciences, LLC
- Amira Pharmaceuticals, Inc.
- Amylin Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Bristol-Myers Company
- Bristol-Myers K.K.
- Bristol-Myers Squibb
- Cardioxyl Pharmaceuticals
- Celgene Corporation
- Cormorant Pharmaceuticals
- Delinia, Inc.
- EngMab AG
- Flexus Biosciences, Inc.
- Gloucester Pharmaceuticals, Inc.
- ißeCa Therapeutics
- IFM Therapeutics
- Impact Biomedicines, Inc.
- Inhibitex, Inc.
- iPierian Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Kosan
- Medarex, Inc.
- Padlock Therapeutics, Inc.
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- Turning Point Therapeutics Inc.
- Westwood-Squibb Pharmaceuticals
- X-BODY, Inc.
- ZymoGenetics, Inc.
- Forbius
- MyoKardia Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice